How many investments has Bain Capital Life Sciences made?

Bain Capital Life Sciences has 113 tracked investments, 31 of which have exited, including 11 dated in the last 24 months.

What stage does Bain Capital Life Sciences invest at?

Bain Capital Life Sciences invests at the Series B, Series C, Growth, Late Stage stages.

What sectors does Bain Capital Life Sciences focus on?

Bain Capital Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Bain Capital Life Sciences located?

Bain Capital Life Sciences is headquartered in Boston, US.

Does Bain Capital Life Sciences lead rounds?

Bain Capital Life Sciences has led 9 of the 21 rounds where its role is on record.

Who does Bain Capital Life Sciences co-invest with?

Bain Capital Life Sciences most often shares deals with RA Capital, Foresite Capital, Frazier Life Sciences, among 162 tracked co-investors.

What size deals does Bain Capital Life Sciences back?

Across 6 deals with disclosed amounts, Bain Capital Life Sciences has joined rounds of $100M – $250M (median $105M).

Bain Capital Life Sciences

Venture capitaloperating company · company profile

Boston · Series B–Late Stage · 31 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Bain Capital Life Sciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Bain Capital Life Sciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Bain Capital Life Sciences targets biopharmaceutical, medical device, diagnostic, and life science tool companies globally with a focus on addressing unmet medical needs. The team leverages extensive public and private investing expertise, operating and consulting experience, and deep scientific and medical knowledge to invest at scale and provide strategic support during critical value-creation phases. The firm pursues a science-first diligence approach to build a diverse portfolio of high-impact, value-creating companies in the life sciences sector.

Invests inBiotech Digital Health Healthtech Medical Devices Boston Global New York

Source: firm website, verified Sep 26, 2026.

Leave your own feedback

Stage

Series B–Late Stage

Boston, NY, US

Instruments

Equity

Founded

2016

Last 12 months

8 investments

Tracked investments

113

Unicorns

IPOs

Acquisitions

Team · 31 people

from the firm's website & public directories

Amir Zamani· Partner· Bostonin

Amir Zamani is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He was previously a Partner at McKinsey & Company, where he worked in the Biopharmaceutical and Medical Products Practice, and earlier was a resident in Plastic Surgery at the University of Pennsylvania. He earned his MD from The Johns Hopkins University School of Medicine and holds a BS in biological sciences and a BA in economics from Stanford University.

Andrew Hack· Partner, Life Sciences· Bostonin

Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.

Nicholas Downing· Partner· Boston

Nicholas Downing is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He previously was a resident physician at Brigham and Women's Hospital in Boston and worked as a consultant at McKinsey & Company, serving pharmaceutical, hospital, and financial services clients. He has authored more than 40 peer-reviewed articles and holds a chemistry degree from Harvard College and an MD from Yale University School of Medicine.

Ricky Lijing Sun· Partner· Boston

Ricky Sun is a Partner on Bain Capital's Life Sciences team, which he joined in 2016. Before Bain Capital, he was Director of Corporate Development and Strategy at Biogen, a Vice President at BlackRock, and a healthcare analyst at Citadel, Alyeska Investment Group, Lehman Brothers, and Morgan Stanley; he began his career as a senior scientist at Ironwood Pharmaceuticals. He holds a PhD in chemistry and chemical biology from Harvard, an MBA from NYU Stern, and a BA in chemistry from Berea College.

Adam M. Koppel· Partner· Bostonin

Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.

Evan Greif· Principal· Bostonin

Evan Greif is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he worked as an Analyst covering healthcare at Orbis Investments and as an Associate Consultant at Bain & Company. He holds a BA in applied mathematics and an MA in statistics from Harvard University, along with a MAST in pure mathematics from Cambridge University.

John Trzupek· Managing Director· Bostonin

John Trzupek joined Bain Capital in 2025 as a Managing Director on the Life Sciences team. He previously served as COO and CFO at Abata Therapeutics and Chief Business Officer at KSQ Therapeutics, and held business and scientific roles at Pfizer, including Director of Strategy for inflammation and immunology. He began his career as a Research Fellow at Memorial Sloan-Kettering Cancer Center.

Lei Meng· Managing Director· Bostonin

Lei Meng is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2024. She previously worked in therapeutics private investments at Avidity Partners and held roles in marketing analytics and business development at Allergan, as well as earlier positions at Merck & Co, Forest Labs, McKinsey & Company, and Samlyn Capital. She holds an MA in chemistry from Harvard University, an MBA from INSEAD, and a BA in biochemistry from Barnard College, Columbia University.

Leonard Feiner· Principal· Bostonin

Leonard Feiner, MD, PhD, is a Principal on the Life Sciences team at Bain Capital, which he joined in 2021. Before that, he worked as a vitreoretinal surgeon and served as principal investigator on over 50 clinical trials covering conditions such as macular degeneration, diabetic macular edema, and retinal vein occlusion. He holds a degree in mechanical and aerospace engineering from Princeton University and an MD/PhD from the University of Pennsylvania, with an ophthalmology residency at Penn and a surgical retina fellowship at Washington University in St. Louis.

Matthew Calistri· Managing Director· Bostonin

Matthew Calistri is a Managing Director in the Portfolio Group of Bain Capital's Life Sciences business, which he joined in 2024. He previously spent four years at Cerevel Therapeutics, serving as VP of Investor Relations and VP of Corporate Strategy, and held investor relations roles at Sage and Biogen. Earlier in his career he worked in financial services at Gerson Lehrman Group, ITG, UBS, Bankers Trust, and E&Y, and he holds an MBA in finance from the University of Chicago Booth School of Business and a BS in accounting from Fordham University.

Renjie Wang· Managing Director· Shanghaiin

Renjie Wang is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2014. She previously worked at Hony Capital, where she closed buyout, minority investment, and privatization transactions in the healthcare sector. She holds a master of finance from Peking University and a BA in economics from Fudan University.

Will Cozean· Managing Director· Melbourne

Will Cozean is a Managing Director on Bain Capital's Life Sciences team, which he joined in 2013. He previously worked on the firm's North America Private Equity team in the Healthcare vertical, as well as its Industrial and Technology verticals, and earlier was a consultant at McKinsey & Company in Atlanta. He holds an MBA from Harvard Business School (Baker Scholar) and a BS in commerce from the University of Virginia (Jefferson Scholar).

Drew Field· Principal· Bostonin

Drew Field is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he was a management consultant at Bain & Company in New York, working with healthcare and private equity clients, and previously held commercial strategy and investor relations roles at a biotech company. He holds a BA in biology and economics from Dartmouth College.

Jonah Cashdan· Principal· New Yorkin

Jonah Cashdan is a Principal on the Life Sciences team at Bain Capital, which he joined in 2018. He previously worked in J.P. Morgan's healthcare investment banking group on M&A and financings for pharmaceutical, biotech, and medtech clients, and earlier studied synaptic physiology and sensory system development in labs at Georgetown University. He holds a BS in Neurobiology from Georgetown University.

Alyson Goff· Associate· Bostonin

Alyson Goff joined Bain Capital in 2025 as an Associate in the Portfolio Group for the Life Sciences business. Before that, she worked as a management consultant at Guidehouse in Boston, advising life-science sector clients on strategic initiatives. She holds an MS in biotechnology enterprise and entrepreneurship from Johns Hopkins University and a BA in biology from Boston University.

Amarilice Young· Associate General Counsel, Life Sciences· Boston

Amarilice Young joined Bain Capital in 2025 as Associate General Counsel for Life Sciences. She was previously a partner in the Life Sciences group at Goodwin Procter LLP. She holds a JD from University of Pennsylvania Law School and a BA in American Studies from Cornell University, and is a member of the Massachusetts and New York state bars.

Chiaka Ibe· Associate· Bostonin

Chiaka Ibe is an Associate on the Bain Capital Life Sciences team, which she joined in 2024. She was previously a management consultant at Bain & Company, advising clients in the Private Equity Group and Healthcare & Life Sciences practice, and worked as an analyst on the Health & Life Sciences team at Gates Ventures. She holds a BA in international health and human biology from Brown University.

Daniyal Sachee· Associate· Bostonin

Daniyal Sachee is an Associate on the Life Sciences team at Bain Capital, which he joined in 2025. He previously worked in the healthcare investment banking group at Goldman Sachs, advising on M&A, debt and equity financings, and royalty monetizations across the biotech and pharmaceutical sectors, and earlier conducted research on rare epilepsy-related disorders at Boston Children's Hospital. He holds a BA in Computational Neuroscience from Harvard.

Greg Koskinas· Chief Financial Officer, Life Sciences· Bostonin

Greg Koskinas is Chief Financial Officer for the Life Sciences business at Bain Capital, which he first joined in 2000 and rejoined in 2024. He was an original member of the firm's Absolute Return Capital business, overseeing trading and operational functions, and earlier worked in the finance group of the Public Equity business. Before returning to Bain Capital, he served as Chief Operating Officer and Chief Compliance Officer at ThornTree Capital Partners. He holds a BA in business and economics from Lafayette College.

Isaac Cheng· Vice President· Bostonin

Isaac Cheng is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2024. He previously held business development and strategy roles in the pharmaceuticals unit at Johnson & Johnson, and evaluated business development and licensing opportunities across pharmaceuticals, MedTech, and services at AbbVie (via its acquisition of Allergan). He began his life sciences career as a management consultant at ZS Associates.

Jay Corrigan· Group Chief Financial Officer, Private Markets· Bostonin

Jay Corrigan is a Partner and Group Chief Financial Officer for Private Markets at Bain Capital, which he joined in 1996. He oversees the finance teams across the firm's Private Equity, Venture, Crypto, Double Impact, Life Sciences, Tech Opportunities, and Real Estate businesses, and also serves as CFO for Double Impact. Before Bain Capital he worked for three years at Ernst & Young, and he holds a BS in accounting from Fordham University.

Jennie Daisak· Vice President· Bostonin

Jennie Daisak is a Vice President on the Life Sciences team at Bain Capital, which she joined in 2021. Before Bain Capital, she worked in J.P. Morgan's healthcare investment banking group, advising biotechnology and pharmaceutical clients on M&A and debt/equity financings. She graduated from the University of Pennsylvania's Vagelos Program in Life Sciences & Management, earning a BA in biology and a BS in economics from the Wharton School with a finance concentration.

Kristen Deftos· Partner and Head of Human Resources, Double Impact, Life Sciences, Real Estate & Tech Opportunities· Bostonin

Kristen Deftos is a Partner and Head of Human Resources at Bain Capital, where she has worked since 2012, overseeing talent acquisition, performance management, and organizational development across the Double Impact, Life Sciences, Real Estate, and Tech Opportunities teams. Before Bain Capital, she held HR relationship management and global talent acquisition roles at Wellington Management Company and earlier worked in HR and recruiting at J.P. Morgan. She holds an AB from Bowdoin College and an MA in organizational psychology from Columbia University Teachers' College.

Melaku Arega· Vice President· Bostonin

Melaku Arega is a Vice President on Bain Capital's Life Sciences team, which he joined in 2022. Before that, he was a medical student at Harvard Medical School, receiving clinical training at Beth Israel Medical Center and other Harvard-affiliated hospitals, and conducted research on cancer care disparities. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and a BS in neuroscience and molecular & cellular biology from Johns Hopkins University.

Melissa Danforth· General Counsel, Life Sciences· Bostonin

Molly Lawrence· Vice President, Human Resources, Life Sciences· Boston

Molly Lawrence joined Bain Capital in 2025 as a Vice President of Human Resources, where she leads recruiting, development, and engagement efforts for the Life Sciences team. She previously served as Vice President of Talent Management and Development at Audax Private Equity and held talent roles at Bain & Company. She holds a BA from Dartmouth College.

Sharad Goyal· Senior Vice President and Head of IT, Private Markets· Boston

Sharad Goyal is Senior Vice President and Head of IT for Private Markets at Bain Capital, which he joined in 2007. Before Bain Capital, he held technology consulting roles in the Global Capital Markets division of Sapient (now Publicis.Sapient). He holds an MBA in finance from Management Development Institute in India, along with a master's in computer science and a bachelor's in finance.

Shuvam Chaudhuri· Associate· Bostonin

Shuvam Chaudhuri is an Associate on the Life Sciences team at Bain Capital, which he joined in 2023, having previously served as a Life Sciences Fellow. He completed his doctoral research at Northwestern University, studying transcriptional mechanisms of immune cell differentiation in cancer, infection, and autoimmunity, and earlier worked in antiviral drug discovery at Janssen Research and Development.

Jeffrey Schwartz· Executive Officer

Julie Yang· Associate· Boston, Massachusetts

Michael Cooney· Vice President· Boston

Michael Cooney is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2021 after serving as a Life Sciences fellow. Before Bain Capital, he was a graduate student researcher in the Department of Genetics at Harvard Medical School, focusing on genomic instability and epigenetic dysfunction in aging, and earlier worked at Genocea Biosciences on pre-clinical and clinical research into T-cell-inducing vaccines. He holds a PhD in biological and biomedical sciences from Harvard University and BS degrees in biology and biotechnology from Tufts University.

Founder mafia

2 people who came through Bain Capital Life Sciences went on to found or lead other companies.

Benjamin NyeSenior Advisor, Fmr Co-Managing PartnerFounded Turbonomic Kees KruythoffSenior Advisor Bain CapitalFounded LIVEKINDLY Collective

What they invest in

from 87 of 113 portfolio companies

Biotech ×68Healthtech ×56Medical Devices ×31Digital Health ×11AI & Machine Learning ×8Deep Tech ×6Enterprise Software ×4SaaS ×4

HQs:United States×61Germany×2Switzerland×1United Kingdom×1Hong Kong×1Ireland×1

Who they back

founder profiles across 30 portfolio companies

47%

solo founders

14 of 30 mapped founding teams

18%

repeat founders

of 22 founders with career history

~3 yrs

old at investment

median across 17 dated deals

Founding team size:solo founder×142 founders×143 founders×14+ founders×1

Where their founders studiedfrom 19 founders with education data

University of California, Berkeley ×3Brown University ×2Harvard Business School ×2Massachusetts Institute of Technology ×2

What their founders studiedfrom 19 founders with field-of-study data

Life Sciences ×5Engineering ×4Business & Management ×3Chemistry ×3Economics ×2

Where their founders worked beforefrom 22 founders with career history

Atlas Venture ×2

6 founders hold a PhD · 3 hold an MBA (of 20 with degree data)

Investments · 113 tracked

founders shown can be your intro path

By year:2026 · 6 2025 · 5 2024 · 2 2022 · 6 2021 · 8 2020 · 6 2019 · 4 2017 · 1 2016 · 1 2015 · 241 dated

Solid Biosciencessolidbio.com in 𝕏NASDAQ: SLDBOct 2020

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)

Board seat Adam M. Koppel· per SEC Form D

Co-investorsForesite Capital RA Capital Bain Capital

Xilio Therapeuticsxiliotx.com inNASDAQ: XLOFeb 2021

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)in Katarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Board seat Andrew Hack· per SEC Form D

Co-investorsBay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital RiverVest Venture Partners +9 more

A Place for Momfiscloudservices.comNASDAQ: GDRXacquired by Exit Blackstone · Jul 2025 · $2.6B

A Place for Mom is a U.S. and Canadian senior care referral marketplace connecting families with senior living and home care providers.

Vernon Hills, US

Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities Bessemer Venture Partners Blue Sea Capital Bosch Ventures Clayton Dubilier & Rice +38 more

Alkermesalkermes.com inNASDAQ: ALKS

Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.

BiotechHealthtechMedical Devices

Richard F. Pops(Chairman of the Board, former CEO)Joshua Reed(Senior Vice President, Chief Financial Officer)in Blair C. Jackson(President & Chief Executive Officer)inDavid J. Gaffin(Executive Vice President, Chief Legal Officer and Chief Compliance Officer; Secretary)inCraig C. Hopkinson(Executive Vice President, Research and Development and Chief Medical Officer)C. Todd Nichols(Senior Vice President, Chief Commercial Officer)in

Co-investorsCardinal Partners Vedanta Capital Hatteras Venture Partners

Amylyxamylyx.com in 𝕏NASDAQ: AMLX

Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.

BiotechHealthtechCambridge, US

Justin Klee(Director)in Joshua Cohen(Founder)in

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

Co-investorsAlpha Wave Global ALS Investment Fund Avoro Capital Advisors

Arcutisarcutis.com in 𝕏NASDAQ: ARQTOct 2019

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

BiotechHealthtechMedical DevicesWestlake Village, US

Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)

Board Patrick Heron(Director)in Daniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsFrazier Life Sciences RA Capital

Atea Pharmaceuticalsateapharma.comNASDAQ: AVIR

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in

Co-investorsATEM Capital Fund RA Capital

C4 Therapeuticsc4therapeutics.com in 𝕏NASDAQ: CCCCDec 2015

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

Kenneth C. Anderson(Director)Andrew J. Hirsch(Director and Chief Executive Officer)in

BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)

Co-investors3E Bioventures Capital Nextech Invest RA Capital Cobro Ventures

Cabaletta Biocabalettabio.com in 𝕏NASDAQ: CABA

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.

BiotechHealthtechRadnor, US

Steven Nichtberger(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)

Board Brian Daniels(Director)in

Co-investors5AM Ventures Deerfield Management Company

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Atlas Venture Foresite Capital Frazier Life Sciences OrbiMed 5AM Ventures +7 more

Freenomefreenome.com in 𝕏NASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US

Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRA Capital Agent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company +15 more

HeartFlowheartflow.com in 𝕏NASDAQ: HTFL

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US

Christopher K. Zarins(Executive Officer, Director)in Charles A. Taylor(Executive Officer, Director)inNicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)inH. Baird Radford, III(Executive Officer)John Farquhar(President, Chief Executive Officer & Director)in

Co-investors3Spoke Capital Blue Venture Funds Emergent Medical Partners, LLP Khosla Ventures Lifeforce Capital Lotus Capital +3 more

Invivydinvivyd.com in 𝕏NASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsForesite Capital MRL Ventures Fund Premji Invest RA Capital GV (Google Ventures)Mithril Capital Management +2 more

Kestra Medical Technologieskestramedical.com inNASDAQ: KMTS

Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.

Digital HealthHardwareHealthtechMedical Devices

Brian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTimothy Moran(Chief Business Officer)

Co-investorsAndera Partners Longitude Capital Star51 Capital Bain Capital

Kymera Therapeuticskymeratx.com in 𝕏NASDAQ: KYMR

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in Bruce Booth(Chair)in

Co-investorsAtlas Venture Avoro Capital Advisors Bessemer Venture Partners Hatteras Venture Partners MRL Ventures Fund Nextech Invest +7 more

Kyverna Therapeuticskyvernatx.com inNASDAQ: KYTXNov 2021

Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.

BiotechEmeryville, US

Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in

Co-investorsVida Ventures Westlake Village BioPartners Gilead Sciences Insight Partners Kleiner Perkins Northpond Ventures +3 more

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsCheyenne Ventures Claremont Creek Ventures Foresite Capital Harmony Partners HBM Healthcare Investments Lightspeed Venture Partners +4 more

Olema Pharmaceuticalsolema.com in 𝕏NASDAQ: OLMA

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in

Co-investorsAvoro Capital Advisors Foresite Capital Lightspeed Venture Partners RA Capital Wellington Management Biotechnology Value Fund +2 more

Replimunereplimune.com in 𝕏NASDAQ: REPL

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsAtlas Venture Foresite Capital REDMILE

Revolution Medicinesrevmed.com inNASDAQ: RVMD

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsForesite Capital Gen Capital GV (Google Ventures)Illinois Ventures Nextech Invest The Column Group+2 more

Savarasavarapharma.com inNASDAQ: SVRADec 2019

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.

BiotechHealthtechMedical DevicesAustin, US

Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)inMike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)inSantosh J. Vetticaden(Executive Officer)Gregory D. Gorgas(Executive Officer)Patrick Keran(Executive Officer)

Co-investorsCentral Texas Angel Network Green Park & Golf Ventures Keiretsu Forum Moore Venture Partners New Enterprise Associates (NEA)

Tarsus Pharmaceuticalstarsusrx.com in 𝕏NASDAQ: TARS

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

Bobak Azamian(Founder)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)in Dianne Whitfield(Chief Human Resources Officer)inElizabeth Yeu-Lin(Chief Medical Officer)

Co-investorsAPERTURE Venture Partners Flying L Partners Frazier Life Sciences Visionary Ventures Vivo Capital RTW Investments L.P.

Upstream Bioupstreambio.com in 𝕏NASDAQ: UPB

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)in Allison Ambrose(General Counsel)in Aaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsOrbiMed Access Industries Access Biotechnology Decheng Capital HBM Healthcare Investments HBM Partners +5 more

X4 Pharmax4pharma.com in 𝕏NASDAQ: XFOR

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in

Co-investorsLumira Ventures New Enterprise Associates (NEA)Partners Resolute Thynk Capital Advent Life Sciences Omega Funds +1 more

Abcuroabcuro.comAug 2026✓ verified

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsNew Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures REDMILE +9 more

ADARx Pharmaceuticalsadarx.com in✓ verified

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Co-investorsOrbiMed SR One Capital Management Lilly Asia Ventures T. Rowe Price Ascenta Capital TCG Crossover +3 more

Merida Biosciencesmeridabio.com in✓ verified

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in

Co-investorsThird Rock Ventures GV (Google Ventures)Biotechnology Value Fund The Engine Ventures

Swixx Biopharmaswixxbiopharma.com in✓ verified

Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsHBM Partners Mérieux Equity Partners SK Capital Partners HBM Healthcare Investments

Affinivaxaffinivax.com in 𝕏Jan 2021

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Board seat Andrew Hack· per SEC Form D

Co-investorsEcoR1 Capital Foresite Capital Viking Global Bain Capital Rock Springs Capital T. Rowe Price

Aptinyxaptinyx.comDec 2017

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seat Adam M. Koppel· per SEC Form D

Co-investorsFrazier Life Sciences Latterell Venture Partners Longitude Capital OUP (Osage University Partners)Agent Capital Bain Capital +3 more

Areteia Therapeuticsareteiatx.com inJun 2022Defunct

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in

BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)

Board seat Adam M. Koppel· per SEC Form D

Co-investorsARCH Venture Partners GV (Google Ventures)Solas BioVentures Viking Global Access Biotechnology Maverick Capital +3 more

Imperative Care Incimperativecare.com in 𝕏Nov 2019

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in

BoardJames Rogers(Director)Stacy Enxing Seng(Director)

Board seat Andrew Hack· per SEC Form D

Co-investorsAscension Ventures Catalio Capital Management, LP Delos Capital FemHealth Ventures Lightstone Ventures

JenaValvejenavalve.comJan 2020 · $100M

JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.

Digital HealthHealthtechMedical DevicesIrvine, US

Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)

Board Arnd Kaltofen(Director)inErik Amble(Director)

Board seat Andrew Hack· per SEC Form D

Co-investorsAndera Partners Rosetta Capital Ltd.VI Partners Atlas Venture Gimv Innovatus Capital Partners +5 more

Nuvalentnuvalent.com in 𝕏Apr 2021

Nuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies.

BiotechHealthtechCambridge, US

Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)Alex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)

Board seat Andrew Hack· per SEC Form D

Co-investorsAvoro Capital Advisors Viking Global Wellington Management Deerfield Management Company

AdvanCell Isotopesadvancell.com.au inJun 2026

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)in Aaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsCatalio Capital Management, LP Proto Axiom Sanofi Ventures SV Health Investors Tenmile Abingworth +2 more

Afferaaffera.com in 𝕏

Affera develops a medical technology platform for treating cardiac arrhythmias, including atrial fibrillation, using innovative ablation solutions.

HealthtechMedical DevicesNewton, US

Doron Harlev(CEO, Founder)in

Co-investorsBAMCAP Elysia Capital

Aiolos Bioaiolosbio.com in 𝕏

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsRA Capital Sofinnova Ventures Atlas Venture Forbion

Alkeuspharmaalkeuspharma.com in 𝕏

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)in

Co-investorsSofinnova Ventures TCG Crossover Wellington Management

Amunix Pharmaceuticalsamunix.comMar 2021 · $117M

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

BiotechSouth San Francisco, US

Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)

Co-investorsFrazier Life Sciences Longitude Capital Viking Global BlackRock Casdin Capital Franklin Templeton +6 more

Annexonannexonbio.com in 𝕏Jul 2020 · $100M

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)

Co-investorsCorrelation Ventures New Enterprise Associates (NEA)BlackRock Blackstone Life Sciences Clarus Ventures Deerfield Management Company +2 more

Bain Capitalbaincapital.com in 𝕏

Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.

Sector AgnosticBoston, US

Co-investorsBain Capital Double Impact Fund LP Bain Capital Tech Opportunities BCI SDV Accel Bain Capital +2 more

Bain Capital Creditbaincapitalcredit.com in 𝕏

Bain Capital Credit is an investment firm specializing in credit strategies including liquid and structured credit, leveraged loans, high-yield bonds, CLOs, and direct lending to middle-market companies.

Fintech

Co-investorsBain Capital Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities

Bain Capital Private Equitybaincapitalprivateequity.com in 𝕏

Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.

Boston, US

Co-investorsBain Capital Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities Two Bear Capital

Bain Capital Real Estatebaincapitalrealestate.com in 𝕏

Bain Capital Real Estate is an investment firm focused on acquiring and operating real estate assets in niche, difficult-to-access sectors driven by long-term economic and secular trends.

PropTechBoston, US

Co-investorsBain Capital Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities

Bain Capital Special Situationsbaincapitalspecialsituations.com in 𝕏

Bain Capital Special Situations is a private investment firm that combines private equity, private credit, and asset-backed capital to source and structure specialized deals across asset classes.

FintechSector AgnosticHong Kong, HK

Co-investorsBain Capital Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities Fidelity Investments Gallatin Point Capital

Bain Double Impact IIbaincapitaldoubleimpact.com in 𝕏

Bain Capital Double Impact is an investment firm established in 2015 that funds companies generating both competitive financial returns and measurable social or environmental impact, with focus areas spanning healthcare access, economic opportunity, and environmental sustainability.

EdTechHealthtechImpact & Social Good

Co-investorsBain Capital Bain Capital Tech Opportunities Blue Haven Initiative

Beelinebeeline.com inJun 2026 · $126.3M

Beeline provides vendor management system (VMS) software for managing contingent and external workforces, including staffing suppliers and shift-based labor.

Future of WorkHR TechSaaS

Co-investorsAcadian Ventures Management, Llc

Beeline Medicinesbeelinemedicines.com in

Beeline Medicines is a biopharmaceutical company developing medicines for patients with serious diseases.

BiotechHealthtechMedical DevicesStamford, US

Dr. Badreddin Edris(President and Chief Operating Officer)Saqib Islam(Chief Executive Officer)in Nathalie Franchimont(Chief Medical Officer)in

Co-investorsBain Capital

Cardurioncardurion.com inJul 2024 · $260M

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)in

Co-investorsBain Capital Ascenta Capital Delos Capital Digitalis Ventures New Enterprise Associates (NEA)Bain Capital Tech Opportunities +4 more

Cerevasccerevasc.com in 𝕏May 2020

CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.

BiotechHealthtechMedical DevicesAuburndale, US

Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)inLeslie Teso-Lichtman(Executive Officer)inFrederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)

Cidara Therapeuticscidara.com in 𝕏

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)in Paul Daruwala(Executive Officer)in

Co-investors5AM Ventures Aisling Capital Frazier Life Sciences RA Capital Vivo Capital Canaan Partners +1 more

Clade Therapeutics inApr 2024

BiotechCambridge, US

Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsLifeSci Venture Partners Casdin Capital Venrock Healthcare Capital Partners

Constellation Pharmaconstellationpharma.com in 𝕏acquired by Novartis

Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)

Co-investorsAvoro Capital Advisors The Column Group Venrock Third Rock Ventures

Dicerna Pharmaceuticalsdicerna.com 𝕏

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsAccess Biotechnology Ridgeback Capital Oxford Bioscience Partners RA Capital

Dynavaxdynavax.com in 𝕏acquired by Sanofi · Dec 2025 · $2.2B

Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology.

BiotechHealthtechDüsseldorf, DE

Ryan Spencer(Chief Executive Officer)inDavid Novack(President and Chief Operating Officer)inRobert Janssen(Chief Medical Officer and Senior Vice President, Clinical Development)inKelly MacDonald(Chief Financial Officer)inJeff Coon(Chief Human Resources Officer)Donn Casale(Chief Commercial Officer)in

Co-investorsHealthCap Sanderling Ventures

Emalexemalex.com 𝕏Nov 2022 · $250M

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechDigital Health

Co-investorsParagon Biosciences LLC Valor Equity Partners Fidelity Investments

Emalex Biosciencesemalexbiosciences.com 𝕏Nov 2022 · $250M

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechMedical Devices

Jeff Aronin(Founder)

Co-investorsParagon Biosciences LLC Fidelity Investments Valor Equity Partners

Gynesonicsgynesonics.com 𝕏acquired by Hologic

FemTechHealthtechMedical DevicesRedwood City, US

Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)

BoardKen Haas(Director)Jonathan MacQuitty(Director)in Mike Carusi(Director)inDoug Fisher(Director)

Co-investorsAmzak Health Endeavour Vision FemHealth Ventures Kaiser Permanente Ventures Kluz Ventures Lightstone Ventures +6 more

Imperativeimperative.com in 𝕏Mar 2026 · $100M

Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.

AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US

Aaron Hurst(Founder)in

Co-investorsEmpire Angels Voyager Capital Ally Bridge Group Amed Ventures Ascension Ventures Catalio Capital Management +4 more

InflaRxinflarx.de

InflaRx is a biopharmaceutical company developing anti-C5a and anti-C5aR complement inhibitors targeting the complement activation factor C5a and its receptor.

BiotechHealthtechJena, DE

Co-investorsRA Capital

Interius BioTherapeuticsinteriusbio.comSeries A · May 2021 · $76M

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in

BoardTomas Kiselak(Director)

Co-investorsAgent Capital DC Investment Partners Longwood Fund OUP (Osage University Partners)Pfizer Venture Investments Quan Capital +3 more

Japan - 日本baincapital.co.jp

Bain Capital is a private equity investment firm with a Tokyo office that provides capital and strategic support to Japanese mid-market and large enterprises pursuing growth, restructuring, and business succession.

Enterprise SoftwareTokyo, JP

Co-investorsBain Capital Bain Capital Double Impact Fund LP Bain Capital Tech Opportunities

Jnana Therapeuticsjnanatx.com in 𝕏Nov 2022 · $107Macquired by Otsuka

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)Annie C. Chen(Director)

Co-investorsAvalon BioVentures Pfizer Venture Investments RA Capital Pfizer Ventures Polaris Partners Versant Ventures

Kailerakailera.com in 𝕏

Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Catalio Capital Management, LP

Longevitilongeviti.com in 𝕏Aug 2025 · $10M

Longeviti Neuro Solutions develops cranial implant platforms for complex brain surgery, including patient-specific and off-the-shelf implants that restore skull contour and enable real-time post-operative ultrasound imaging.

HealthtechMedical Devices

Jesse Christopher(CEO & Co-founder)in

Co-investorsMaryland TEDCO TEDCO

Marinus Pharmaceuticalsmarinuspharma.com

BiotechRadnor, US

Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAvoro Capital Advisors Canaan Partners Connecticut Innovations Sofinnova Ventures Domain Associates Flare Capital Partners +1 more

Mersana Therapeuticsmersana.com 𝕏Jun 2016Acquired

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsF-Prime Capital Lightstone Ventures New Enterprise Associates (NEA)Nextech Invest Pfizer Venture Investments Rho Ventures +3 more

NewAmsterdam Pharmanewamsterdampharma.com in 𝕏

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsBioGeneration Ventures EQT Life Sciences Frazier Life Sciences Forbion

Nimbusnimbus.energySep 2022 · $125M

Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.

Deep TechEnergyHardware

Michael Gorman(Founder)in

Co-investorsFoothill Ventures Access Biotechnology Atlas Venture Biotechnology Value Fund Commodore Capital GV (Google Ventures)+2 more

Nimbusnimbusweb.me in 𝕏Sep 2022 · $125M

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPre-Seed to Succeed Yellow Rocks!Access Biotechnology Atlas Venture Biotechnology Value Fund Commodore Capital +3 more

Nimbus Therapeuticsnimbustx.com in

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsAccess Biotechnology Atlas Venture Dementia Discovery Fund GV (Google Ventures)Lightstone Ventures Pfizer Venture Investments+4 more

Nurix Therapeuticsnurixtx.com in 𝕏

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Arthur T. Sands(Executive Officer, Director)in Gwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

Board David Goeddel(Director)inMark Goldsmith(Director)

Co-investorsEcoR1 Capital Foresite Capital Sofinnova Ventures The Column Group Wellington Management Third Rock Ventures

Octant Biooctant.bio in 𝕏Oct 2025 · $175M

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US

Sri Kosuri(Founder)inRamsey Homsany(Founder)inRobert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)

Co-investorsAndreessen Horowitz +ND Capital 8VC Carbon Silicon Catalio Capital Management, LP Explorer Investments +9 more

Pharvarispharvaris.com in 𝕏

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsForesite Capital Kurma Partners venBio Partners Viking Global

Pillar Biosciencespillarbiosci.com inMay 2025 · $35M

Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.

BiotechDigital HealthHealthtechMedical DevicesNatick, US

Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)

Co-investorsCatalio Capital Management, LP HB Ventures Soleus Capital

Riskgamingriskgaming.com in

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in

Board Joshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)

Co-investorsCisco Investments Foresite Capital Lux Capital Dimension Capital

Rivus Pharmaceuticals, Inc.rivuspharma.com in 𝕏

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in

Board Francesco De Rubertis(Director)in

Co-investorsMedicxi Longitude Capital RA Capital

Synthekinesynthekine.com in 𝕏

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapital The Column Group Canaan Partners RA Capital TCG Crossover Deerfield Management Company +2 more

Syremis Therapeuticssyremis.com inDec 2025 · $165M

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsThird Rock Ventures GV (Google Ventures)

Syros Pharmaceuticals, Inc.syros.comDec 2020

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

BiotechCambridge, US

Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)

Co-investorsAisling Capital ARCH Venture Partners Quan Capital Alexandria Ally Bridge Group Bain Capital +11 more

Tech Opportunitiesbaincapitaltechopportunities.com

Bain Capital Tech Opportunities is a technology-focused investment firm that provides growth capital, along with strategic and operational support, to entrepreneurs and management teams during expansion phases.

Enterprise SoftwareFintechSaaS

Co-investorsBain Capital Bain Capital Double Impact Fund LP

Tenvietenvie.com inJan 2025

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.

BiotechMedical Devices

Tony Estrada(President & Chief Executive Officer)in

Co-investorsARCH Venture Partners F-Prime Capital Digitalis Ventures Forbion Mubadala Capital

Timberlynetimberlyne-tx.com in

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets.

BiotechHealthtech

ViaCyteviacyte.com

Transforming the lives of patients through a functional cure for Type 1 Diabetes

BiotechSan Diego, US

Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)Howard Foyt(Executive Officer)inKevin D'Amour(Executive Officer)in

Co-investorsArtis Ventures ATEL Ventures RA Capital Sanderling Ventures The Vertical Group Johnson & Johnson Innovation – JJDC +1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Cardurion Pharmaceuticals, Inc.AavantiBioAmylyx PharmaceuticalsAngitiaApreoArcutis BiotherapeuticsAtsenaAvistone PharmaceuticalsBridge TO Life Caldera Therapeutics, Inc.Cerevel TherapeuticsCidaraDianthusEyeBioFISHugel PharmaInsuranceRapid Micro BiosciencesReplimune GroupRiver RenalSeránSpringWorks TherapeuticsSyremisSyros PharmaceuticalsTanabe PharmaTenacia BiotechnologyThird Harmonic BioThrive Earlier DetectionTruvic Medical

Exits · 31

25 IPOs · 6 acquisitions · showing 29

Solid BiosciencesNASDAQ: SLDBXilio TherapeuticsNASDAQ: XLOA Place for MomNASDAQ: GDRXAlkermesNASDAQ: ALKSAmylyxNASDAQ: AMLXArcutisNASDAQ: ARQTAtea PharmaceuticalsNASDAQ: AVIRC4 TherapeuticsNASDAQ: CCCCCabaletta BioNASDAQ: CABADisc MedicineNASDAQ: IRONFreenomeNASDAQ: FRNMHeartFlowNASDAQ: HTFLInvivydNASDAQ: IVVDKestra Medical TechnologiesNASDAQ: KMTSKymera TherapeuticsNASDAQ: KYMRKyverna TherapeuticsNASDAQ: KYTXNateraNASDAQ: NTRAOlema PharmaceuticalsNASDAQ: OLMAReplimuneNASDAQ: REPLRevolution MedicinesNASDAQ: RVMDSavaraNASDAQ: SVRATarsus PharmaceuticalsNASDAQ: TARSUpstream BioNASDAQ: UPBX4 PharmaNASDAQ: XFORConstellation Pharmaacq. by NovartisDynavaxacq. by SanofiEyeBioacq. by MerckGynesonicsacq. by HologicJnana Therapeuticsacq. by Otsuka

Portfolio news

latest coverage across their companies

Kyverna Therapeutics to Present at Upcoming September 2026 Investor Conferences - BioSpace

Kyverna Therapeutics · biospace.com · Sep 3, 2026

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY | Invivyd

Invivyd · investors.invivyd.com · Sep 1, 2026

Abcuro Raises $66M in Series D Funding

Abcuro · finsmes.com · Aug 18, 2026

AdvanCell has filed a notice of an exempt offering of securities to raise $315 Million in New Funding. - intelligence360

AdvanCell Isotopes · intelligence360.news · Aug 4, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026 - BioSpace

Alkermes · biospace.com · Jul 15, 2026

Beeline Medicines Raises $126.3M in Series A Extension Funding

Beeline Medicines · finsmes.com · Jul 6, 2026

Iran, data centers, Victorian AI - by Danny Crichton

Riskgaming · blog.riskgaming.com · Apr 3, 2026

Pillar Biosciences Raises $34.5M in Funding

Pillar Biosciences · finsmes.com · May 27, 2025

Fund performance · per public LP disclosures

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Bain Capital Life Sciences Fund IV. L.P.LPs: New Jersey Division of Investment, California Public Employees' Retirement System, Maryland State Retirement and Pension System	2024	—	—	0.00x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Replimune	9.2%	$15.00	Jul 2018	$42.6M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Public market activity · per SEC filings

what is this? ⓘ

4 insider ownership filings (Forms 3/4/5)

at Kailera Therapeutics, Inc. (KLRA), Olema Pharmaceuticals, Inc. (OLMA)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Bain Capital Life Sciences made?: Bain Capital Life Sciences has 113 tracked investments, 31 of which have exited, including 11 dated in the last 24 months.
What stage does Bain Capital Life Sciences invest at?: Bain Capital Life Sciences invests at the Series B, Series C, Growth, Late Stage stages.
What sectors does Bain Capital Life Sciences focus on?: Bain Capital Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Bain Capital Life Sciences located?: Bain Capital Life Sciences is headquartered in Boston, US.
Does Bain Capital Life Sciences lead rounds?: Bain Capital Life Sciences has led 9 of the 21 rounds where its role is on record.
Who does Bain Capital Life Sciences co-invest with?: Bain Capital Life Sciences most often shares deals with RA Capital, Foresite Capital, Frazier Life Sciences, among 162 tracked co-investors.
What size deals does Bain Capital Life Sciences back?: Across 6 deals with disclosed amounts, Bain Capital Life Sciences has joined rounds of $100M – $250M (median $105M).

Co-investors · 11

RA Capital

RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.

Both backed · 23

Bain Capital

Bain Capital is a global private investment firm operating across private equity, growth and venture, credit, real assets, and capital solutions, partnering with companies to create value across sectors and regions.

Both backed · 20

Kestra Medical Technologies Solid Biosciences Xilio Therapeutics Affinivax Aptinyx Bain Capital Bain Capital Credit Bain Capital Private Equity Bain Capital Real Estate Bain Capital Special Situations Bain Double Impact II Beeline Medicines Cardurion Cardurion Pharmaceuticals, Inc.Japan - 日本 SpringWorks Therapeutics Syros Pharmaceuticals, Inc.Tech OpportunitiesCerevel TherapeuticsInsurance

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 10

A Place for Mom Freenome InvivydRevolution MedicinesAreteia Therapeutics Cardurion Merida Biosciences Nimbus Syremis TherapeuticsNimbus Therapeutics

$250K – $50M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 4

Areteia Therapeutics Syros Pharmaceuticals, Inc.TenvieNimbus Therapeutics

$50K – $250M

Agent Capital

Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.

Both backed · 3

Freenome Aptinyx Interius BioTherapeutics

SV Angel

SV Angel is a San Francisco-based firm that invests long-term in founders, supporting them with advice, introductions, and network access at key business inflection points.

Both backed · 1

Octant Bio

$150K – $20M

General Atlantic

General Atlantic is a global investment firm that partners with entrepreneurs and companies to build long-term value through growth equity, credit, energy transition, and infrastructure strategies.

Both backed · 1

A Place for Mom

$10M – $1B

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm investing in innovative healthcare companies.

Both backed · 1

Abcuro

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

Both backed · 1

Disc Medicine

$1.1M – $54M

Unknown Ventures

Unknown Ventures is a venture studio based in Austin that provides funding and operational support to early-stage startups at the pre-seed to Series A stage. The firm backs founders seeking to create innovative solutions that improve human experience.

Triatomic Capital

Triatomic Capital is an investment firm focused on 'century defining' themes across advanced technology areas including AI infrastructure, semiconductors, materials, robotics, and energy.

$100K – $1M

Firms observed investing alongside Bain Capital Life Sciences, from public investor directories. Shared companies are the overlap with Bain Capital Life Sciences's recorded portfolio.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.

$1M – $20M

Norwest Venture Partners

Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.

$10M – $30M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Investors & VC Firms in Global Growth Investors & VC Firms Healthtech Investors & VC Firms Series B Investors & VC Firms Healthtech Investors & VC Firms in North America Biotech Investors & VC Firms Healthtech Investors & VC Firms in United States Growth Investors & VC Firms in North America Growth Investors & VC Firms in United States Investors & VC Firms in New York